AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01796093 — intervention group
Intervention type: DRUG
Intervention: Digoxin and ivabradine
Description: No more details
Study NCT04599114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VIRTUES
Description: VIRTUES is a digital health platform that offers 2 way communication between clinicians and patients to address symptoms stemming from atrial fibrillation.
Study NCT02028884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satralizumab
Description: Satralizumab will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
Study NCT02028884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
Study NCT02028884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Baseline Treatment
Description: As specified in the protocol, one of the following drugs at a stable dose is required as monotherapy for baseline treatment during the double-blind period: azathioprine (AZA); mycophenolate mofetil (MMF); or oral corticosteroids (CS). For participants aged 12 to 17 years at the time of informed consent, baseline treatment with AZA or MMF in combination with oral CS is also permitted. Change or termination of baseline treatment is only permitted during the open-label extension period.
Study NCT02028884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baseline Treatment
Description: As specified in the protocol, one of the following drugs at a stable dose is required as monotherapy for baseline treatment during the double-blind period: azathioprine (AZA); mycophenolate mofetil (MMF); or oral corticosteroids (CS). For participants aged 12 to 17 years at the time of informed consent, baseline treatment with AZA or MMF in combination with oral CS is also permitted. Change or termination of baseline treatment is only permitted during the open-label extension period.
Study NCT03412526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Reduced intensity, myeloablative, lymphodepleting regimen (25 mg/m2 for 3 days)
Study NCT03412526 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Total Body Radiation (TBR) (2 Gray in a single treatment) for 1 day
Study NCT04228965 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Varenicline
Description: Varenicline is a medication approved by the Food and Drug Administration for the treatment of tobacco use disorder among adults (ages 18 and over). In this study, all participants will be administered active medication for the recommended 12 week treatment period. The standard dose titration schedule will be used, which includes 0.5 mg once per day (q.d.) on Days 1-3, 0.5 mg twice per day (b.i.d.) on Days 4-7, and 1.0 mg b.i.d. starting on Day 8. Dosing of 2.0 mg per day will be maintained for the next 11 weeks, for a total of 12 weeks of active treatment for all study participants.
Study NCT04228965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline is a medication approved by the Food and Drug Administration for the treatment of tobacco use disorder among adults (ages 18 and over). In this study, all participants will be administered active medication for the recommended 12 week treatment period. The standard dose titration schedule will be used, which includes 0.5 mg once per day (q.d.) on Days 1-3, 0.5 mg twice per day (b.i.d.) on Days 4-7, and 1.0 mg b.i.d. starting on Day 8. Dosing of 2.0 mg per day will be maintained for the next 11 weeks, for a total of 12 weeks of active treatment for all study participants.
Study NCT04228965 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Contingency Management
Description: Contingency management procedures will be implemented and financial incentives will be provided at weekly visits contingent on tobacco abstinence verified through urinary qualitative cotinine (starting at Week 2). A set amount of $20 per study visit will be delivered based on a negative qualitative urinary cotinine result.
Study NCT03412526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIL administration
Description: TIL Administration
Study NCT03412526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: bolus high-dose (720,000 IU/kg) IL-2 is administered to the patients every 8 hours, to tolerance. A maximum of 10 doses are given to the patients.
Study NCT04228965 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Description: Contingency management procedures will be implemented and financial incentives will be provided at weekly visits contingent on tobacco abstinence verified through urinary qualitative cotinine (starting at Week 2). A set amount of $20 per study visit will be delivered based on a negative qualitative urinary cotinine result.
Study NCT01254630 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V212
Description: V212 viral antigen for HZ, 0.5 mL subcutaneous (SC) injection per dose, in a four dose regimen, approximately 30 days apart.
Study NCT01254630 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaccine stabilizer for V212 with no virus antigen, 0.5 mL SC injection per dose, in a four dose regimen, approximately 30 days apart.
Study NCT03715101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Open-label, one-sequence, multiple administration
Study NCT01909453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: MEK162- Orally 15 mg tablets
Study NCT01909453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vemurafenib
Description: Tablets in bottles or blisters 240 mg
Study NCT04228965 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Counseling
Description: Psychosocial counseling will be administered by trained research staff leading up to the target quit date and throughout the study. Counseling will include motivational enhancement for medication adherence and tobacco cessation. The content of counseling will be skills-based and will focus on enlisting social support, recognizing smoking triggers, managing craving/withdrawal/stress, etc.
Study NCT04228965 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Psychosocial counseling will be administered by trained research staff leading up to the target quit date and throughout the study. Counseling will include motivational enhancement for medication adherence and tobacco cessation. The content of counseling will be skills-based and will focus on enlisting social support, recognizing smoking triggers, managing craving/withdrawal/stress, etc.
Study NCT00424450 — intervention group
Intervention type: PROCEDURE
Intervention: lower limb artery bypass surgery
Description: bypass of severe atherosclerotic vascular lesion
Study NCT00424450 — intervention group
Intervention type: PROCEDURE
Intervention: percutaneous angioplasty (PTA)
Description: PTA of severe atherosclerotic lesion
Study NCT04150055 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Coach
Description: Mindfulness Coach is an mHealth delivered mindfulness therapy.
Study NCT04040946 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MIBI scintigraphy
Description: Performing a MIBI scintigraphy, then, in the case of negativity, a single F18-choline PET
Study NCT04040946 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: F18-choline PET
Description: Realization of a F18-choline PET, then, in case of negativity, a MIBI scintigraphy
Study NCT01689636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc 99m EC20
Study NCT00912860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: serum free Avonex given IM once a week
Study NCT02398656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: TNK will be administered as a single intravenous bolus over 1-2 minutes within 90 minutes of the CT scan.
Study NCT02398656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiplatelet treatment
Description: Low dose aspirin (single agent) will be the choice of most physicians, some Investigators will chose to use the combination of aspirin and clopidogrel.
Study NCT01020383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALX-0081
Description: 4 i.v. bolus injections, once every 6 hours; first dose of 6 mg, three subsequent doses of 4 mg
Study NCT01020383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ReoPro®
Description: 0.25 mg/kg i.v. bolus injection followed by continuous i.v. infusion of 0.125 µg/kg/min (to a max. of 10 µg/min) for 12 hours
Study NCT04232774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Neurotronic arterial ablation catheter
Description: a sterile, single use catheter (device) for delivering chemical agent to achieve perivascular denervation.
Study NCT00589212 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GliaSite Radiation Therapy System
Description: GliaSite RTS is designed to deliver intracavitary radiation therapy for brain tumors. Following surgical resection, the balloon catheter is inflated to fill the cavity and Iotrex radiotherapy solution infused. It is a single applicator system that provides a uniform and conformal dose to the resection cavity.
Study NCT00618280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine nasal spray
Description: 0,5 mg nicotine nasal spray or placebo (pepperspray)
Study NCT00618280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nicotine nasal spray
Description: 0,5 mg nicotine nasal spray or placebo (pepperspray)
Study NCT03299491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MWA intervention
Description: The MWA intervention will involve upgrading existing maternity waiting areas to ensure that essential supplies and services are available to create a comfortable environment for women to temporarily reside in and have easy access to skilled obstetric services.
Study NCT03299491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IEC intervention
Description: Community and religious leaders will each attend one-day workshops designed using participatory, adult learning methods to help participants better understand the importance of maternal health care services, identify barriers to accessing care and to strategize how to promote utilization of services. Half-day workshops will conducted in subsequent years to build on shared experiences.~Health extension workers will attend 3-day workshops to identify enablers and barriers to implementation of the safe motherhood components of the health extension program and strategize on how to engage community and religious leaders to support access to maternal health care services in their communities.~Half-day workshops will conducted in subsequent years for each of the participant groups to build on shared experiences.
Study NCT03631563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppressive Agent
Description: ATG-Fresenius versus ATG
Study NCT03631563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunosuppressive Agent
Description: ATG-Fresenius versus ATG
Study NCT02141347 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tremelimumab
Description: Tremelimumab administered intravenously
Study NCT02141347 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MEDI4736
Description: MEDI4736 administered intravenously.
Study NCT00697892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir
Description: Two tablets of lopinavir 200mg / ritonavir 50mg orally twice daily with food for 26 days
Study NCT00697892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz
Description: One 600mg tablet orally once daily before bedtime on an empty stomach for 26 days
Study NCT00697892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemether/lumefantrine
Description: 4 tablets of artemether 20mg/lumefantrine 120mg twice daily with food. 2 three-day courses will be administered (with washout in between) during the duration of the trial.
Study NCT01440244 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cervical mediastinoscopy
Description: minimally invasive technique to perform pleural evaluation, pleural biopsy and pleurodesis
Study NCT01306669 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine
Description: single dose of 0.5ml of Trivalent influenza vaccine for season will be administered into deltoid muscle of non-dominant arm
Study NCT01306669 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Single dose of 0.5ml of normal saline will be administered into deltoid muscle of non-dominant arm
Study NCT03588975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MACI
Description: autologous cultured chondrocytes on porcine collagen membrane
Study NCT03588975 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microfracture
Description: Arthroscopic microfracture treatment
Study NCT00603447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib for Injection was administered intravenously over 10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for the first 12 cycles. Each dose of Carfilzomib for Injection was normalized to body surface area.
Study NCT00603447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide was administered orally on Days 1 to 21 of each 28-day cycle.
Study NCT00603447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg orally or intravenous equivalent was administered 30 minutes to 4 hours before carfilzomib on Days 1, 8, and 15, as well as on Day 22 of each 28-day cycle.
Study NCT03293264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training group
Description: Exercise training will consist of 3 - 6 sessions per week and will cumulate in 150 min net exercise time per week. Heart rates during exercise sessions will be monitored with the aim of physical activities at moderate-intensity. Exercises will be individualized to reach the best possible improvements to the cardiovascular and musculoskeletal system. Possible disciples will include but are not limited to: cycling, rowing (ergometer), swimming, walking, nordic-walking, running, arm-cycle-ergometer or cross-trainer as well as fitness courses offered from occupational or private providers. Everyday activities which reach an effective heart rate range can account for exercise training on a home-based basis .~Advise on complementary individual strength and coordination exercises will be added to the training program. A nutrition analyses will be completed by every subject to account for special needs of the metabolic syndrome.
Study NCT04164628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Description: Quality of life will be assessed with Nottingham Health Profile
Study NCT04162366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan 25 mg
Description: Tablet, oral use once daily
Study NCT04162366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet, oral use once daily
Study NCT04106830 — intervention group
Intervention type: DRUG
Intervention: Intravenous steroid
Description: This study does not limit treatment methods.patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. The HD-S treatment course referred to intravenous administration of 1 g of glucocorticoid daily for 3 consecutive days and continuous dose 240 mg reduction for 60mg oral administration. Immunomodulatory therapies are necessary for the remission stage. The treatment methods include: Azathioprine (start at 50 mg per day, add 50 mg per week to 2 mg/kg.d); Mycophenolate Mofetil (The initial dose was 0.25g bid, add 0.5g per week to 0.75g bid); and Rituximab (500 mg on the 1st day, the 15th day, then 500mg per half year).
Study NCT03566108 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VISTA
Description: Vestibular incision supraperiosteal tunnel access (VISTA) incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
Study NCT03566108 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: STA
Description: Sulcular tunnel access incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
Study NCT03529331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate Immediate Release
Description: 15 mg Morphine Sulfate Immediate Release (MSIR) tablet 4 times a day for 5 days
Study NCT03529331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone/Acetaminophen
Description: 5 mg of Oxycodone/Acetaminophen (Percocet) tablet 4 times a day for 5 days
Study NCT03529331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone/Acetaminophen
Description: 5 mg of Hydrocodone/Acetaminophen (Vicodin) tablet 4 times a day for 5 days
Study NCT04275934 — intervention group
Intervention type: BEHAVIORAL
Intervention: Health Management; Blood Pressure
Description: Pharmacists will work with the patient/study subject, referred to as the participant hereafter, and the participant's other health care providers to manage their blood pressure, making recommendations for medication and lifestyle adjustments as needed.
Study NCT02318537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Solution
Description: An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
Study NCT02318537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Solution
Description: A matching oral solution containing no cannabidiol.
Study NCT01847742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing Therapy
Study NCT04306029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postpartum Family Planning Package
Description: Postpartum Family Planning Package, which consists of provider education on contraceptive delivery in the immediate postpartum period and promotion of the WHO MEC/PFP Compendium mobile application.
Study NCT04108234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR071603
Description: HR071603 monotherapy ,nasal spray
Study NCT04108234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo,nasal spray
Study NCT00316992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon and Placebo
Description: Ramelteon 8 mg, tablets, orally, one night only and Ramelteon placebo-matching tablets, orally, one night only.
Study NCT02592525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IP-SDM training for health professionals
Description: Multifaceted SDM training program for providers: i) 1.5-hour online tutorial, ii) 3.5-hour skills building workshop; iii) video-clip demonstrating SDM in the context of an IP home care team with an aging adult making a decision about location of care (to be used with clients and providers as well); and iv) performance feedback to providers (role play during the workshop).
Study NCT01363648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: choline alfoscerate
Description: Participants were randomly assigned to twice-daily doses of 400mg choline alphoscerate (alpha-glyceryl phosphoryl choline, Gliatilin®)
Study NCT01363648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (for choline alphoscerate)
Description: Pill manufactured to mimic choline alfoscerate 400mg tablet
Study NCT02827227 — intervention group
Intervention type: BIOLOGICAL
Intervention: lymphocytes immunophenotyping
Description: The lymphocytes immunophenotyping were performed from fresh EDTA-anticoagulated blood harvested during a routine follow-up of patients in HIV Lyon centers.~HIV patients with a known history of PHI and a minimum of 2 years of effective cART (\< 200 copies/mL) without interruption or virological failure were included in 2 centers in Lyon (Croix-Rousse and Edouard Herriot hospital).~Baseline factors at the time of PHI, delay, type and duration of first and duration of total cART, CMV status, nadir CD4 cells count and level of activation markers on CD4 and CD8 cells (CD38 and HLA-DR) at the time of the study were assessed.~Patients with hepatitis C or B virus co-infection or with a history of neoplasia or immunosuppressive therapy after the date of PIH were excluded.
Study NCT02245984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: paper based nursing process
Description: for two weeks, students in paper based nursing group will be implemented paper nursing process for patients.
Study NCT02245984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electronic nursing process
Description: for each of the groups separately-training program aimed to education the nursing process and how to do it (including the definition of the nursing process, advantages and its implementation and how to collect data using patient assessment forms Gordon) in the form of workshops a day (5 hours) will be implemented. Nursing process education in the two groups will similar but two hours of the program in each groups is devoted to practical training on how to implement. After completing the training program, students learn about the nursing process will be determined in the same way. Then for two weeks, students in Group A and Group B will be implemented paper and electronic nursing process for patients.
Study NCT02235805 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium Citrate
Description: One capsule thrice daily that contains magnesium citrate (total daily dose: 350 mg elemental magnesium) at breakfast, lunch and dinner for 24 weeks